BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 29, 2026
Home » Blogs » BioWorld MedTech Perspectives » Be honest, be open, and be upfront about devices

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Be honest, be open, and be upfront about devices

May 6, 2011
By Omar Ford

A couple of weeks ago I interviewed PixelOptics' president/CEO Ron Blum, about a technology called emPower, a device that could eventually replace bifocals.

Now there's one thing you need to know about the interview. 

 Blum is one of those people that med-tech journalists just love to talk to. He’s honest, upfront and has a sort of passion about his product that you just don’t see that often. He’s not  regurgitating facts, or bedazzling you with technical terms that can sometimes go straight over your head.

But rather, Blum is a master of his craft. And if  emPower is anything like its CEO, then we’re going to have a lot less people wearing bifocals in the near future - because he is just that convincing.   

And here’s what I think some med-tech companies are missing. They’re missing that one person who is tailor made to get their point across. Companies are missing that person who has the power and the authority to have an honest conversation about the technology and kick out a lot of P.R. jargon that tends to creep up in interviews.

My only problem with the Blum interview is that it couldn’t go longer. But alas deadlines are a harsh reality for daily publications.

My point is this, when companies are trying to get out the message about their products, they should talk a little bit about what the product could mean for the patient. Don’t give numbers or stats, those will most likely be presented in the press release. Instead try to personalize the experience, let the interviewer and the audience know what’s at stake.

Blum, with so much media attention placed on emPower was fully aware of the stakes and was brutally honest with Medical Device Daily about what that meant for him and the company.

He told me, “When you have this kind of attention on a [global scale], which is at least in our industry unprecedented, it's tremendous pressure on a company like PixelOptics to make sure its product lives up to the promise that we deliver what it is we say we're going to deliver."

If only more companies could open up like this.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • Subsense BCI platform

    Next wave of BCI firms builds on pioneers to tackle challenges

    BioWorld
    With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
  • Boehringer Ingelheim identifies new mGlu3 receptor agonists

    BioWorld Science
    Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
  • GT-02897 exerts efficacy in preclinical multiple myeloma

    BioWorld Science
    Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing